rns!6 Oct 2020 17:48
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, on the UK Government's first order for one million COVID-19 lateral flow antibody tests (the "AbC-19™ Rapid test").
This first order is part of the UK Government's plans to roll-out COVID-19 surveillance studies to help build a picture of how the virus has spread across the country.
The AbC-19™ Rapid test uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need for a patient sample to be sent to a laboratory. The test is currently CE-Marked for professional use and can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers, at the point-of-care. The UK-RTC are seeking approval from the MHRA for self-test use.
The UK-RTC members are in the final stages of formalising an agreement for the supply of goods from members to Abingdon Health, following the Memorandum of Understanding that was signed in April 2020. Omega expects to manufacture approximately 175,000 of these first 1 million tests but over the term of this supply agreement, Omega will manufacture not less than 25% of the demand from total orders placed, either from the UK Government or, where allowed, third party customers.
The UK-RTC is reproduced in full at the end of this statement.
The Company expects to provide a trading update for the six months to 30 September 2020 in late October 2020.
Colin King, CEO of Omega, commented: "I am delighted that the UK-RTC has now received its first contract from the UK Government for our COVID-19 lateral flow antibody test. We believe that the AbC-19™ Rapid test has the immediate opportunity to allow the UK to build a swift and clear picture of how the virus has spread throughout the population. It also has the potential to be deployed in conjunction with vaccine candidates to help assess initial immune responses."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC
Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd
Tel: 020 7220 0500
Geoff Nash/Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited
Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303
Press Release from the UK-RTC (issued on 6 October 2020)
UK-RTC AbC-19TM Rapid Test receives successful independent PHE evaluation
T
Sign In
Follow the stocks
